V5 tag antibody - #T0057
(1)
(3)
製品: | V5 tag antibody |
カタログ: | T0057 |
タンパク質の説明: | Mouse monoclonal antibody to V5 tag |
アプリケーション: | WB |
反応性: | All |
ユニプロット: | |
RRID: | AB_2846184 |
製品説明
ソース:
Mouse
アプリケーション:
WB(1:2000-1:20000)
*The optimal dilutions should be determined by the end user.
*Tips:
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
反応性:
All
クローナリティ:
Monoclonal [AFB17768]
特異性:
T0057 detects a small epitope, termed Pk, present on the P/V proteins of the paramyxovirus, SV5.
RRID:
AB_2846184
引用形式: Affinity Biosciences Cat# T0057, RRID:AB_2846184.
引用形式: Affinity Biosciences Cat# T0057, RRID:AB_2846184.
コンジュゲート:
Unconjugated.
精製:
Protein G purification.
保存:
Mouse IgG1 in 10 mM PBS (pH 7.4), 0.1mg/ml BSA , 50% glycerol and 1% ProClin™ 300. Store at -20 °C. Stable for 12 months from date of receipt.
別名:
折りたたみ/展開
V5-Tag;Protein Rev;
免疫原
免疫原:
Mice were infected with the paramyxovirus SV5, Simian-Virus 5.
参考文献
1). OTUB1 contributes to the stability and function of Influenza A virus NS2. PLoS pathogens, 2024
(PubMed: 38814988)
[IF=6.7]
Application: WB Species: Human Sample: HEK293T cells
Fig 1. Ubiquitination and instability of NS2. (A) HEK293T cells were transfected with pHA-NS2. At 24 h post-transfection, cells were treated with DMSO (lane 1) or MG132 (lane 2) for 14 h. Proteins in the lysates were then detected by immunoblotting with anti-HA and anti-α-tubulin antibodies. (B) HEK293T cells were transfected with pcDNA-HA (lane 1) or pHA-NS2 (lane 2), and then treated with MG132. Proteins in the lysate were immunoprecipitated (IP) with anti-HA antibody and immunoblotted (IB) with anti-Ub (upper panel) and anti-HA (lower panel) antibodies (lanes 1–2). (C) H1299 cells were transfected with pV5-Ub. At 24 h post-transfection, cells were infected with A/Puerto Rico/8/1934 (H1N1) at an MOI of 2 for 0 h (lanes 1, 6), 6 h (lanes 2, 7), 9 h (lanes 3, 8), 12 h (lanes 4, 9), and 18 h (lanes 5,10). Proteins in the lysates were immunoprecipitated with anti-NS2 antibody and immunoblotted with anti-V5 and anti-NS2 to determine ubiquitinated NS2 and non-ubiquitinated NS2, respectively (lanes 1–5). (D) HEK293T cells were cotransfected with pHA-NS2 and pcDNA-NV5 (lane 1), pHA-NS2 and pV5-Ub (lane 2), or pHA-NS2 and pV5-Ub(K0) (lane 3). At 24 h after transfection, cells were treated with MG132 for 14 h. Proteins in the lysates were immunoprecipitated (IP) with anti-HA antibody and immunoblotted (IB) with anti-V5 antibody to show ubiquitinated HA-NS2. The input (B, lanes 3–4; C, lanes 6–10; D, lanes 1–3, lower panel) shows the amount of total ubiquitinated proteins (Ub-P) (B), V5-Ub conjugated proteins (V5-Ub-P) (C, D), NS2 (C), HA-NS2 (D), and α-tubulin (B-D) in the lysates as detected by immunoblotting with anti-Ub, anti-V5, anti-NS2, anti-HA, and anti-α-tubulin antibodies, respectively. PUNS2: polyubiquitinated HA-NS2 (B and D) or NS2 (C). “–” represents an empty vector, pcDNA-HA (A, B) and pcDNA-NV5 (D). (E-H) HEK293T cells were cotransfected with (E) pHA-NS2 and pcDNA-NV5, (F) pHA-NS2 and pV5-Ub, or (G) pHA-NS2 and pV5-Ub(K0). At 36 h post-transfection, cells were treated with cycloheximide (CHX). Proteins in the lysate were detected by immunoblotting with anti-HA, anti-V5, and anti-α-tubulin antibodies at 0, 30, 60, and 120 min after the treatment. (H) Intensity of the HA-NS2 bands in (E-G) was measured with ImageJ and normalized to the intensity of the respective control α-tubulin band. The amount of NS2 at Hour 0 was set to 1. Error bars represent standard error, which was calculated from the results of three independent sets of experiments. *p < 0.05.
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.